PMA device
Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve
Edwards Lifesciences, LLC · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Dec 27, 2018, newest Oct 22, 2026Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
19
Naming "SAPIEN 3 Ultra"
MAUDE reports
10,369
Brand "SAPIEN 3 Ultra", since 2015
PubMed studies
195
Mentioning "SAPIEN 3 Ultra"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
P140031-S202 · Decided Oct 22, 2026 · 188 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValvePMA supplement
P140031-S189 · Decided Feb 3, 2026 · 281 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValvePMA supplement
P140031-S172 · Decided Jun 21, 2024 · 85 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
3 more FDA decisions with a free account
Older decisions: P140031-S141, P140031-S102, P140031-S099, P140031-S085, P140031-S074
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "SAPIEN 3 Ultra", any status and sponsor, newest update first.
- Balloon vs. Self Expanding Transcatheter Valve for Degenerated BioprosthesisPivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028
Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease
Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all
- Comparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve IndicationPivotal-lookingRecruiting
Fundación EPICAcademic, hospital or other
NCT06049654 · 104 participants (planned) · Start Feb 1, 2024 · Primary completion Nov 1, 2027
Device: NVT ALLEGRA TAVI System TF; EDWARDS SAPIEN 3 or SAPIEN ULTRA SYSTEM · For: Aortic Valve Stenosis; Structural Valve Deterioration
Sites: Alessandria, Italy; Brescia, Italy; Perugia, Italy · 12 sites in all
- Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.Pivotal-lookingActive, not recruiting
Christian Juhl TerkelsenAcademic, hospital or other
NCT06470022 · 1,370 participants · Start Aug 9, 2024 · Primary completion Jul 14, 2027
Device: Medtronic Evolut FX; Edwards Sapien 3 Ultra Resilia · For: Aortic Stenosis
Sites: Aarhus, Denmark
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SAPIEN 3 Ultra", and for the whole product code for context.
This brand
10,369 reports: 786 malfunction, 8,434 injury, 1,149 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
2015691-2026-19833 · Received Oct 29, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2015691-2026-19836 · Received Oct 29, 2026 · Event dated Oct 5, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Intravalvular regurgitation
Patient problem as coded: Dyspnea; Fatigue; Heart Failure/Congestive Heart Failure
2015691-2026-19840 · Received Oct 29, 2026 · Event dated Aug 12, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0835-2019 · Started Jan 22, 2019
Reason given: This action has been initiated to address complaint reports received for crimp balloon and inflation balloon component separation during TAVR procedures.
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-2435-2018 · Started Jun 11, 2018
Reason given: SAPIEN 3 THV was packaged with the incorrect valve size with respect to the label.
Cause as FDA categorized it: Labeling False and Misleading · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Z-0293-2018 · Started Jul 21, 2017 · Posted by FDA Jan 10, 2018
Reason given: A component in the Certitude Loader may have a molding overflow defect that could detach during advancement of the delivery system and potentially embolize from the loader into the patient.
Cause as FDA categorized it: Employee error · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Published research
The most relevant PubMed records for "SAPIEN 3 Ultra"[tiab]. The summary above synthesizes these.
- SAPIEN 3 Ultra Resilia: Critical Reflections on Real-World Performance.
Amat-Santos IJ, García-Gómez M · JACC Cardiovasc Interv · 2024Editorial, Comment
- SAPIEN 3 Ultra Transcatheter Aortic Valve Device: Two Sides of the Moon.
Barbanti M, Costa G · JACC Cardiovasc Interv · 2020Editorial, Comment
- ACURATE neo2 versus SAPIEN 3 Ultra for transcatheter aortic valve implantation.
Pellegrini C, Rheude T, Renker M, et al. · EuroIntervention · 2023
- Performance and outcomes of the SAPIEN 3 Ultra RESILIA transcatheter heart valve in the OCEAN-TAVI registry.
Yamamoto M, Yashima F, Shirai S, et al. · EuroIntervention · 2024
- SAPIEN 3 Ultra: better sealing, reduced paravalvular leak and a move in the right direction?
Reardon MJ, Goel SS · EuroIntervention · 2023
- Outcomes of SAPIEN 3 Ultra TAVR in Extremely Undersized Versus Equivalent Nominally Sized Anatomies.
Tang GHL, Hooda A, Chuang MA, et al. · JACC Cardiovasc Interv · 2022Letter
- Addressing Unanswered Questions in Hemolysis Following SAPIEN 3 Ultra RESILIA Valve Implantation.
Ahmad A, Ahmad A, Iqbal J, et al. · Am J Cardiol · 2025Editorial
- SAPIEN 3 Ultra - Design and procedural features of a new balloon-expandable valve.
Parma R, Hudziak D, Smolka G, et al. · Cardiol J · 2020
- Minimizing Paravalvular Regurgitation With the Novel SAPIEN 3 Ultra TAVR Prosthesis: A Real-World Comparison Study.
Tamm AR, Hell MM, Geyer M, et al. · Front Cardiovasc Med · 2021
- ACURATE neo2 Versus SAPIEN 3 Ultra Transcatheter Heart Valve in Severe Aortic Valve Calcification: A Propensity-Matched Analysis.
Eckel C, Kim WK, Sötemann D, et al. · Circ Cardiovasc Interv · 2024Comparative Study
- Incidence, predictors, and clinical impact of hypoattenuating leaflet thickening following SAPIEN 3 Ultra RESILIA implantation.
Ishizu K, Shirai S, Hayashi M, et al. · EuroIntervention · 2025Observational Study
- Routine postdilation after 23ߙmm Sapien 3 Ultra implantation in the aortic position.
Leone PP, Sturla M, Spring AM, et al. · Catheter Cardiovasc Interv · 2024Observational Study, Comparative Study
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
- LOTUS Edge Valve SystemBoston Scientific Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.